Full Text View
Tabular View
No Study Results Posted
Related Studies
Investigation of the Efficacy and Safety of Drotrecogin Alfa (Activated) in Pediatric Severe Sepsis
This study has been completed.
Study NCT00049764   Information provided by Eli Lilly and Company
First Received: November 13, 2002   Last Updated: November 15, 2007   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Sepsis
More general conditions related to this trial
Infection
Inflammation
Pathologic Processes
Systemic Inflammatory Response Syndrome
Interventions listed in this trial
Drotrecogin alfa (activated)
Placebo
Additional drug interventions recognized in this trial
Drotrecogin alfa activated
Protein C
More general drug interventions related to this trial
Anti-Infective Agents
Anticoagulants
Cardiovascular Agents
Fibrin Modulating Agents
Fibrinolytic Agents
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Eli Lilly and Company


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services